Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)

NCT03070002 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT03070002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03070002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Terminated
Start date
October 19, 2017
Completion date
April 24, 2018
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma metastatic in the bone, circulating tumor cell count, estrogen receptor positive, her2/neu negative, progesterone receptor positive, stage iv breast cancer